Category: Biolase Technology Inc.Syndicate content

Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves

September 2, 2014 by Brad Perriello

Bluegrass Vascular Technologies taps former ArthroCare R&D chief Gabriele Niederauer to be its new president & CEO.

Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves

Bluegrass Vascular Technologies said it named Gabriele Niederauer its new president & CEO, hard on the heels of a Series A funding round that brought in $4.5 million for its Surfacer central venous catheter.

Medtronic CEO Ishrak seeks to reassure employees on MDT-COV deal | The week in medtech M&A

August 20, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Amid political noise, Ishrak seeks to reassure employees on Medtronic-Covidien deal; Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; Medtronic founder Bakken backs Covidien buy; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Allergan CFO Edwards steps down amid hostile Valeant takeover bid

Amid political noise, Ishrak seeks to reassure employees on Medtronic-Covidien deal

August 15, 2014 by Brad Perriello

Allergan CFO Edwards steps down amid hostile Valeant takeover bid | Personnel Moves

August 18, 2014 by Brad Perriello

Allergan CFO Jeff Edwards is stepping down amid a $44 billion hostile takeover bid from Valeant Pharmaceuticals and Pershing Square Capital Management.

Allergan CFO Edwards steps down amid hostile Valeant takeover bid | Personnel Moves

Allergan (NYSE:AGN) said today that longtime CFO Jeff Edwards is stepping down to honor a commitment he made to his family earlier this year, replaced by treasurer Jim Hindman effective immediately.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biolase ex-CEO demands answers following his board resignation

August 14, 2014 by Arezu Sarvestani

Ousted CEO Federico Pignatelli turns the spotlight on new leadership at his former company after resigning from the board of directors.

Biolase ex-CEO demands answers following his resignation

Former Biolase (NSDQ:BIOL) CEO Federico Pignatelli isn't ready to put down his dukes after dropping his seat on the company's board of directors.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Hologic CEO gives glowing review to major stakeholder and activist investor Carl Icahn | Medtech Wall Street news for the week of August 4, 2014

August 7, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Hologic's CEO praises its activist investor; Lantheus spikes IPO plans; Ex-CEO Pignatelli backs down, but not out, in spat with Biolase; Symmetry Medical sells its OEM biz to Tecomet for $450M; Valeant's hostile takeover hopes fade as Allergan war continues

Hologic's CEO praises its activist investor

August 4, 2014 by Arezu Sarvestani

Hologic CEO MacMillan praises activist investor Icahn

Biolase ex-CEO Pignatelli ditches the board

August 7, 2014 by Arezu Sarvestani

Biolase's scorned former CEO Federico Pignatelli retires from the board of directors, saying that he was effectively forced out by hostilities from other members.

Biolase ex-CEO Pignatelli steps down from board

Former Biolase (NSDQ:BIOL) CEO Federico Pignatelli, who was removed from the corner office by a court order earlier this year, also walked away from the company's board of directors.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp